MedTrace Logo

Nab-PCE vs PC for MM After Failure of Anti-PD-1

NCT03917069 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2019-04-17

No results posted yet for this study

Summary

This is a randomized controlled clinical trial of nab-paclitaxel + carboplatin

* Endostatin for advanced melanoma after failure of PD-1 therapy. The aim was to evaluate the efficacy and safety of nab-paclitaxel+carboplatin
* endostatin versus combination of paclitaxel and carboplatin in patients with advanced melanoma after failure of PD-1 therapy.

Conditions

Interventions

DRUG

Chemotherapeutic Combinations

nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d

DRUG

chemotherapy

paclitaxel 175 mg/m2 d1+Carboplatin AUC=5 d1, q21d

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    lead OTHER

Principal Investigators

  • Jun Guo, Dr. · Peking University Cancer Hospital & Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-23
Primary Completion
2021-09-30
Completion
2022-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03917069 on ClinicalTrials.gov